Recent advancement in breast cancer treatment using CAR T cell therapy:- A review
Breast Cancer arises to be the most diagnosed cancer type in recent decades. It ranks to be the most vulnerable among women in terms of incidence and mortality. In 2020, 2.3 million women were diagnosed with breast cancer, and 6.85 lacs of death were reported globally. Here, we will focus mainly on...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-07-01
|
| Series: | Advances in Cancer Biology - Metastasis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667394023000047 |
| _version_ | 1797799874603778048 |
|---|---|
| author | Anuvab Dey Subhrojyoti Ghosh Shreya Jha Subhranil Hazra Nainika Srivastava Urmimala Chakraborty Anupriya Guha Roy |
| author_facet | Anuvab Dey Subhrojyoti Ghosh Shreya Jha Subhranil Hazra Nainika Srivastava Urmimala Chakraborty Anupriya Guha Roy |
| author_sort | Anuvab Dey |
| collection | DOAJ |
| description | Breast Cancer arises to be the most diagnosed cancer type in recent decades. It ranks to be the most vulnerable among women in terms of incidence and mortality. In 2020, 2.3 million women were diagnosed with breast cancer, and 6.85 lacs of death were reported globally. Here, we will focus mainly on TNBC, the most complicated breast cancer subtype. Therefore, novel treatment modalities are urgently required. Treatments like chemotherapy and radiotherapy limit the efficacy of therapeutic outcomes. Thus, new specific ideas are coming up to find a way out. For triple-negative breast cancer (TNBC), which is currently the most complex and challenging breast cancer subtype to treat, chemotherapy is still the standard of care. There has been a lot of study into novel treatments for people with TNBC because of its poor prognosis and the high chance of clinical recurrence. Chimeric antigen receptor (CAR) T cell-based immunotherapy directs the patient's immune system to recognize and eradicate tumor cells that express tumor-associated antigens (TAAs). It opens up a new area of research. Chimeric Antigen Receptor (CAR-T) cell therapy is an immunotherapy type derived from adoptive T cell relocation. CAR-T cells are well equipped with specific antibodies to identify antigens in self-tumor cells, thus bringing out cytotoxic outcomes. CARs are the modified receptors with improved specificity and responsiveness to intensify the recognition of cancer cells. The therapeutic effects of CAR-T cell treatment, including breast cancer, have not lived up to expectations in solid tumors despite recent triumphs in treating hematologic malignancies. In this review, we will discuss some recent developments in the field of breast cancer-specific immunotherapy using CAR-T. |
| first_indexed | 2024-03-13T04:25:30Z |
| format | Article |
| id | doaj.art-0d8981f82aa149139810e8f8fab16eb2 |
| institution | Directory Open Access Journal |
| issn | 2667-3940 |
| language | English |
| last_indexed | 2024-03-13T04:25:30Z |
| publishDate | 2023-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Advances in Cancer Biology - Metastasis |
| spelling | doaj.art-0d8981f82aa149139810e8f8fab16eb22023-06-20T04:21:27ZengElsevierAdvances in Cancer Biology - Metastasis2667-39402023-07-017100090Recent advancement in breast cancer treatment using CAR T cell therapy:- A reviewAnuvab Dey0Subhrojyoti Ghosh1Shreya Jha2Subhranil Hazra3Nainika Srivastava4Urmimala Chakraborty5Anupriya Guha Roy6Corresponding author. Vill- Madarat Dakshintala, P.O.-Madarat, P.S.-Baruipur, District- South 24 Parganas, West-Bengal, 743610, India.; Department of Biotechnology, Heritage Institute of Technology, Kolkata, IndiaDepartment of Biotechnology, Heritage Institute of Technology, Kolkata, IndiaDepartment of Biotechnology, Heritage Institute of Technology, Kolkata, IndiaDepartment of Biotechnology, Heritage Institute of Technology, Kolkata, IndiaDepartment of Biotechnology, Heritage Institute of Technology, Kolkata, IndiaDepartment of Biotechnology, Heritage Institute of Technology, Kolkata, IndiaDepartment of Biotechnology, Heritage Institute of Technology, Kolkata, IndiaBreast Cancer arises to be the most diagnosed cancer type in recent decades. It ranks to be the most vulnerable among women in terms of incidence and mortality. In 2020, 2.3 million women were diagnosed with breast cancer, and 6.85 lacs of death were reported globally. Here, we will focus mainly on TNBC, the most complicated breast cancer subtype. Therefore, novel treatment modalities are urgently required. Treatments like chemotherapy and radiotherapy limit the efficacy of therapeutic outcomes. Thus, new specific ideas are coming up to find a way out. For triple-negative breast cancer (TNBC), which is currently the most complex and challenging breast cancer subtype to treat, chemotherapy is still the standard of care. There has been a lot of study into novel treatments for people with TNBC because of its poor prognosis and the high chance of clinical recurrence. Chimeric antigen receptor (CAR) T cell-based immunotherapy directs the patient's immune system to recognize and eradicate tumor cells that express tumor-associated antigens (TAAs). It opens up a new area of research. Chimeric Antigen Receptor (CAR-T) cell therapy is an immunotherapy type derived from adoptive T cell relocation. CAR-T cells are well equipped with specific antibodies to identify antigens in self-tumor cells, thus bringing out cytotoxic outcomes. CARs are the modified receptors with improved specificity and responsiveness to intensify the recognition of cancer cells. The therapeutic effects of CAR-T cell treatment, including breast cancer, have not lived up to expectations in solid tumors despite recent triumphs in treating hematologic malignancies. In this review, we will discuss some recent developments in the field of breast cancer-specific immunotherapy using CAR-T.http://www.sciencedirect.com/science/article/pii/S2667394023000047CAR-T cell therapyBreast cancerChimeric antigen receptorImmunotherapyGenetic engineeringTriple-negative breast cancer |
| spellingShingle | Anuvab Dey Subhrojyoti Ghosh Shreya Jha Subhranil Hazra Nainika Srivastava Urmimala Chakraborty Anupriya Guha Roy Recent advancement in breast cancer treatment using CAR T cell therapy:- A review Advances in Cancer Biology - Metastasis CAR-T cell therapy Breast cancer Chimeric antigen receptor Immunotherapy Genetic engineering Triple-negative breast cancer |
| title | Recent advancement in breast cancer treatment using CAR T cell therapy:- A review |
| title_full | Recent advancement in breast cancer treatment using CAR T cell therapy:- A review |
| title_fullStr | Recent advancement in breast cancer treatment using CAR T cell therapy:- A review |
| title_full_unstemmed | Recent advancement in breast cancer treatment using CAR T cell therapy:- A review |
| title_short | Recent advancement in breast cancer treatment using CAR T cell therapy:- A review |
| title_sort | recent advancement in breast cancer treatment using car t cell therapy a review |
| topic | CAR-T cell therapy Breast cancer Chimeric antigen receptor Immunotherapy Genetic engineering Triple-negative breast cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2667394023000047 |
| work_keys_str_mv | AT anuvabdey recentadvancementinbreastcancertreatmentusingcartcelltherapyareview AT subhrojyotighosh recentadvancementinbreastcancertreatmentusingcartcelltherapyareview AT shreyajha recentadvancementinbreastcancertreatmentusingcartcelltherapyareview AT subhranilhazra recentadvancementinbreastcancertreatmentusingcartcelltherapyareview AT nainikasrivastava recentadvancementinbreastcancertreatmentusingcartcelltherapyareview AT urmimalachakraborty recentadvancementinbreastcancertreatmentusingcartcelltherapyareview AT anupriyaguharoy recentadvancementinbreastcancertreatmentusingcartcelltherapyareview |